1. Home
  2. Labeler Index
  3. Novartis Pharmaceuticals Corporation
  4. 0078-1070
  5. Product Images: Cosentyx

Product Images Cosentyx

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. PRINCIPAL DISPLAY PANEL NDC 0078-0639-97 Cosentyx® (secukinumab) Injection Single-use Prefilled Syringe 150 mg/mL 1 Prefilled Syringe ATTENTION: Dispense with enclosed Medication Guide. For Subcutaneous Use Only Sterile Solution - Contains No Preservative Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Rx only NOVARTIS - cosentyx 01
  2. Figure A - cosentyx 02
  3. Figure B - cosentyx 03
  4. Figure C - cosentyx 04
  5. Figure D - cosentyx 05
  6. Figure E - cosentyx 06
  7. Figure F - cosentyx 07
  8. COSENTYX prefilled syringe parts (see Figure A): - cosentyx 08
  9. Figure B - cosentyx 09
  10. Figure C - cosentyx 10
  11. Figure D - cosentyx 11
  12. Figure E - cosentyx 12
  13. Figure F - cosentyx 13
  14. Figure G - cosentyx 14
  15. Figure H - cosentyx 15
  16. Figure I - cosentyx 16
  17. Figure J - cosentyx 17
  18. Figure A - cosentyx 18
  19. Figure B - cosentyx 19
  20. Figure C - cosentyx 20
  21. Figure D - cosentyx 21
  22. Figure E - cosentyx 22
  23. Figure F - cosentyx 23
  24. Figure G - cosentyx 24
  25. Figure H - cosentyx 25
  26. Holding your COSENTYX Sensoready Pen: - cosentyx 26
  27. Figure I - cosentyx 27
  28. Figure J - cosentyx 28
  29. Figure K - cosentyx 29
  30. Figure L - cosentyx 30
  31. Figure M - cosentyx 31
  32. Figure 4: ASAS40 Responses in nr-axSpA1 Study Over Time up to Week 16 - cosentyx 32
  33. PRINCIPAL DISPLAY PANEL NDC 0078-1056-97 Cosentyx® (secukinumab) Injection 75 mg/0.5 mL 1 Single-dose Prefilled Syringe For Subcutaneous Use Only Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. ATTENTION: Dispense with enclosed Medication Guide. NOVARTIS - cosentyx 33
  34. Figure 1: Percent of Patients Achieving ACR 20 Responsea in PsA1 Study Through Week 24 - cosentyx 34
  35. Figure 2: ASAS20 Responses in all AS1 Study Patients Over Time Up to Week 16 - cosentyx 35
  36. Figure 3: ASAS20 Responses in all AS3 Study Patients Over Time Up to Week 16 - cosentyx 36
  37. COSENTYX prefilled syringe parts (see Figure A): - cosentyx 37
  38. Figure B - cosentyx 38
  39. Figure C - cosentyx 39
  40. Figure D - cosentyx 40
  41. Figure E - cosentyx 41
  42. Figure F - cosentyx 42
  43. Figure G - cosentyx 43
  44. Figure H - cosentyx 44
  45. Figure I - cosentyx 45
  46. Figure J - cosentyx 46
  47. cosentyx 47
  48. cosentyx 48

Product Label Images

The following 48 images provide visual information about the product associated with Cosentyx NDC 0078-1070 by Novartis Pharmaceuticals Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PRINCIPAL DISPLAY PANEL NDC 0078-0639-97 Cosentyx® (secukinumab) Injection Single-use Prefilled Syringe 150 mg/mL 1 Prefilled Syringe ATTENTION: Dispense with enclosed Medication Guide. For Subcutaneous Use Only Sterile Solution - Contains No Preservative Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Rx only NOVARTIS - cosentyx 01

PRINCIPAL DISPLAY PANEL NDC 0078-0639-97 Cosentyx® (secukinumab) Injection Single-use Prefilled Syringe 150 mg/mL 1 Prefilled Syringe ATTENTION: Dispense with enclosed Medication Guide. For Subcutaneous Use Only Sterile Solution - Contains No Preservative Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Rx only NOVARTIS - cosentyx 01

This is a description of Cosentyx medication, which is used for subcutaneous injection. The medication comes in the form of a single-dose prefilled syringe containing 150 mg of secukinumab, and should be stored in a refrigerator at a temperature of 2-8°C (36-46°F). The medication can be stored at room temperature for up to 0-30°C (86°F) for a maximum of 4 days, after which it should be discarded. The medication guide enclosed should be followed while dispensing the medication. The medication may contain Latex which may cause an allergic reaction. For more information, visit the Cosentyx official website or call 1-835 NOW-1IOVA (-888-860-6622).*

Figure A - cosentyx 02

Figure A - cosentyx 02

Figure B - cosentyx 03

Figure B - cosentyx 03

Figure C - cosentyx 04

Figure C - cosentyx 04

Figure D - cosentyx 05

Figure D - cosentyx 05

Figure E - cosentyx 06

Figure E - cosentyx 06

Figure F - cosentyx 07

Figure F - cosentyx 07

COSENTYX prefilled syringe parts (see Figure A): - cosentyx 08

COSENTYX prefilled syringe parts (see Figure A): - cosentyx 08

This appears to be a description of a syringe with various features such as finger grips, a needle cap, a viewing window, label & expiration date, guard wings and plunger head. It is likely a medical device used for injecting medication or other substances.*

Figure B - cosentyx 09

Figure B - cosentyx 09

Figure C - cosentyx 10

Figure C - cosentyx 10

Figure D - cosentyx 11

Figure D - cosentyx 11

Figure E - cosentyx 12

Figure E - cosentyx 12

Figure F - cosentyx 13

Figure F - cosentyx 13

Figure G - cosentyx 14

Figure G - cosentyx 14

Figure H - cosentyx 15

Figure H - cosentyx 15

Figure I - cosentyx 16

Figure I - cosentyx 16

Figure J - cosentyx 17

Figure J - cosentyx 17

Figure A - cosentyx 18

Figure A - cosentyx 18

This text describes the features of a needle that includes a needle guard, cap, viewing window, and internal needle cover.*

Figure B - cosentyx 19

Figure B - cosentyx 19

Figure C - cosentyx 20

Figure C - cosentyx 20

Figure D - cosentyx 21

Figure D - cosentyx 21

This text simply states "Viewing window" and does not provide enough context to generate a useful description.*

Figure E - cosentyx 22

Figure E - cosentyx 22

Figure F - cosentyx 23

Figure F - cosentyx 23

Figure G - cosentyx 24

Figure G - cosentyx 24

Figure H - cosentyx 25

Figure H - cosentyx 25

Holding your COSENTYX Sensoready Pen: - cosentyx 26

Holding your COSENTYX Sensoready Pen: - cosentyx 26

Figure I - cosentyx 27

Figure I - cosentyx 27

Figure J - cosentyx 28

Figure J - cosentyx 28

Figure K - cosentyx 29

Figure K - cosentyx 29

Figure L - cosentyx 30

Figure L - cosentyx 30

Figure M - cosentyx 31

Figure M - cosentyx 31

Figure 4: ASAS40 Responses in nr-axSpA1 Study Over Time up to Week 16 - cosentyx 32

Figure 4: ASAS40 Responses in nr-axSpA1 Study Over Time up to Week 16 - cosentyx 32

The text shows a graph of the percentage of responders over time (in weeks) for three different treatments: Cosentyx 150 mg Load, Cosentyx 150 mg No Load, and Placebo. The graph shows that both Cosentyx treatments have a higher percentage of responders than the Placebo, and that the Load treatment appears to have a quicker and more significant effect than the No Load. No further information is available.*

PRINCIPAL DISPLAY PANEL NDC 0078-1056-97 Cosentyx® (secukinumab) Injection 75 mg/0.5 mL 1 Single-dose Prefilled Syringe For Subcutaneous Use Only Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. ATTENTION: Dispense with enclosed Medication Guide. NOVARTIS - cosentyx 33

PRINCIPAL DISPLAY PANEL NDC 0078-1056-97 Cosentyx® (secukinumab) Injection 75 mg/0.5 mL 1 Single-dose Prefilled Syringe For Subcutaneous Use Only Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. ATTENTION: Dispense with enclosed Medication Guide. NOVARTIS - cosentyx 33

Cosentyx is an injectable medication for subcutaneous use for the treatment of plaque psoriasis. The medication significantly reduces inflammation, slows down joint damage, and improves symptoms associated with psoriasis. It is important to store this medication at a temperature between 2°C to 8°C and to discard the unused portion. The drug contains natural rubber latex which may cause an allergic reaction. Patient instructions and drug information are provided.*

Figure 1: Percent of Patients Achieving ACR 20 Responsea in PsA1 Study Through Week 24 - cosentyx 34

Figure 1: Percent of Patients Achieving ACR 20 Responsea in PsA1 Study Through Week 24 - cosentyx 34

This text appears to be a chart or graph displaying the percentage of respondents, time in weeks, and treatment options (10mg Cosenly, Cosentyx 0mg, and placebo). It is not possible to determine the context or purpose of the chart from this limited information.*

Figure 2: ASAS20 Responses in all AS1 Study Patients Over Time Up to Week 16 - cosentyx 35

Figure 2: ASAS20 Responses in all AS1 Study Patients Over Time Up to Week 16 - cosentyx 35

This appears to be a graph or chart showing the percentage of respondents in relation to weeks and treatment (Cosentyx 150mg and Placebo). Without further context, it is not possible to provide a more detailed or accurate description.*

Figure 3: ASAS20 Responses in all AS3 Study Patients Over Time Up to Week 16 - cosentyx 36

Figure 3: ASAS20 Responses in all AS3 Study Patients Over Time Up to Week 16 - cosentyx 36

This appears to be a graph showing the percentage of respondents over time in weeks for different treatments, including Cosenlyx at 150 mg with IV loading and Coseniyx at 300 mg with IV loading, compared to a placebo. The graph shows that both doses of Cosenlyx have a higher percentage of respondents than the placebo.*

COSENTYX prefilled syringe parts (see Figure A): - cosentyx 37

COSENTYX prefilled syringe parts (see Figure A): - cosentyx 37

This appears to be a description of a syringe. It includes features such as finger grips, a plunger, a view window, a needle cap, label and guard wings, and an expiration date label.*

Figure B - cosentyx 38

Figure B - cosentyx 38

Figure C - cosentyx 39

Figure C - cosentyx 39

Figure D - cosentyx 40

Figure D - cosentyx 40

Figure E - cosentyx 41

Figure E - cosentyx 41

Figure F - cosentyx 42

Figure F - cosentyx 42

Figure G - cosentyx 43

Figure G - cosentyx 43

Figure H - cosentyx 44

Figure H - cosentyx 44

Figure I - cosentyx 45

Figure I - cosentyx 45

Figure J - cosentyx 46

Figure J - cosentyx 46

cosentyx 47

cosentyx 47

cosentyx 48

cosentyx 48

This data appears to be from a clinical trial comparing the effectiveness of a drug called Cosentyx with a placebo. The x-axis displays time in days, while the y-axis shows the number of patients at risk. The numbers below the x-axis, however, are not legible or recognizable, so it is not possible to provide further information.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.